The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of ...

Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...

While Illinois joins states challenging cuts to medical research funding, an Illinois State University lab supported by the ...

The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across ...

The Swiss biopharma company said the deal with the German National Association of Statutory Health Insurance Funds (GKV-SV) ...

Pratteln, Switzerland Friday, February 14, 2025, 15:00 Hrs [IST] ...

Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -- Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...